Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. It is a heterogeneous group of diseases that may need very aggressive treatment in some cases. Prognostic evaluation is very important in determining the best treatment. However, in some clinics, access to genetically based and expensive diagnostic methods is limited. In this study, we analyzed the prognostic value of Hemoglobin, Albumin, Lymphocyte and Platelet (HALP) Score and Geriatric Nutritional Risk Index (GNRI) in DLBCL patients. 201 Patients with newly diagnosed DLBLC between 2005 and 2022 were retrospectively evaluated. Optimal cutoff points for the HALP score and the GNRI were calculated with the receiver operating characteristic curve analysis. Kaplan–Meier method was used to compare survival and disease-free survival times between HALP score groups. In the receiver operating characteristic curve analysis, the cutoff points were found 26.17 for HALP, and 99.17 for GNRI. Groups with lower HALP scores and lower GNRIs had significantly shorter overall survival and disease-free survival. Univariate analyses showed that lower HALP score, lower GNRI and higher lactic dehydrogenase, Ann-Arbor stage, International Prognostic Index (IPI), National Comprehensive Cancer Network-IPI and Revised-IPI scores were associated with worse survival rates (P < .05). According to the results of the multivariate Cox regression model, patients with HALP score ≤ 26.17 (OR: 2.32; 95%CI: 1.31–4.11 P = .004) increased the risk of death (P = .001, −2 loglikelihood = 506.15). Similarly, a GNRI score ≤ 99.17 was significantly correlated with worse survival outcomes (P < .001). HALP score and GNRI score are reliable, simple and easily accessible indices that can be used to predict the prognosis of DLBLC patients. DLBLC patients with low HALP score and low GNRI level may be associated with short survival and early nutritional support should be considered.

Background/Objectives: Although outcomes in Hodgkin lymphoma (HL) have improved substantially, patients with advanced-stage disease, comorbidities, or relapsed/refractory presentations can still fare poorly. Blood-based indices of systemic inflammation and nutrition are derived from routine tests, but their value beyond established prognostic models is uncertain. We examined the association of the baseline Gustave Roussy Immune Score (GRIm) and Glasgow Prognostic Score (GPS) with treatment response, progression-free survival (PFS), and overall survival (OS) in HL, focusing on their performance relative to the seven-factor International Prognostic Score (IPS-7). Methods: We retrospectively analysed 110 adults with histologically confirmed HL treated at a tertiary haematology centre between January 2015 and December 2025. GPS, GRIm, and IPS-7 were calculated from data recorded at diagnosis. Treatment response was classified as complete versus non-complete. Outcomes were assessed with Kaplan–Meier analysis, log-rank tests, Cox regression, Harrell’s C-index, and likelihood-ratio testing. Results: Most patients had advanced-stage disease (69.1%) and received ABVD-based treatment (94.5%); complete response was achieved in 90 (81.8%). GPS and GRIm were not significantly associated with non-complete response, whereas IPS-7 was. Over a median follow-up of 39.5 months, 28 patients (25.5%) progressed or died and 17 (15.5%) died. In univariable Cox analysis, high GRIm risk (HR = 2.68, 95% CI 1.17–6.14), higher GPS (HR = 2.18 per point, 95% CI 1.23–3.89), and higher IPS-7 (HR = 2.10 per point, 95% CI 1.59–2.77) predicted shorter PFS. For OS, GPS and IPS-7 were significant, whereas GRIm was not. After adjustment for IPS-7, neither GPS nor GRIm remained independently associated with PFS or OS, and adding either score to IPS-7 produced only small, non-significant gains in discrimination. Conclusions: Baseline GPS and GRIm were associated with survival on univariable analysis, particularly for PFS, but their incremental value beyond IPS-7 was limited. These scores may help describe baseline inflammatory and nutritional risk and should not be regarded as alternatives to established HL prognostic models. In particular, GPS and GRIm were not significantly associated with treatment response and should be viewed as supportive markers requiring external validation, rather than as tools that can independently guide treatment decisions.

Background/Objectives: Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms may influence folate metabolism and DNA synthesis, potentially affecting disease characteristics and clinical outcomes in hematologic malignancies. This study investigated the associations of MTHFR C677T and A1298C polymorphisms with clinical features and survival outcomes in adult patients with acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL). Methods: A total of 92 adult patients with ALL or NHL treated with standard chemotherapy were retrospectively analyzed. MTHFR C677T and A1298C genotypes were determined using real-time polymerase chain reaction. Associations between genotypes and baseline clinical features, treatment response, toxicity, overall survival (OS), and progression-free survival (PFS) were examined. Results: The C677T heterozygous genotype was significantly associated with the presence of B symptoms (p = 0.027). No significant differences were observed across genotypes with respect to other baseline clinical features, treatment response, or treatment-related toxicity. In the overall cohort (ALL + NHL), OS and PFS did not differ significantly by C677T or A1298C genotypes. However, in the NHL cohort, carriers of the C677T variant demonstrated significantly shorter PFS (p = 0.048) and a non-significant trend toward lower OS. This association was also observed in the DLBCL subgroup for PFS (p = 0.043), with a similar non-significant trend observed for OS. Conclusions: Although MTHFR genotyping appears to have limited value for broad clinical stratification, the observed association between the C677T polymorphism and PFS in NHL—particularly in the DLBCL subgroup—suggests a potential subtype-specific relevance that warrants further validation in larger, disease-specific cohorts.

Çalışmamızda esansiyel trombositemi (ET) tanılı hastalarda klinik, laboratuvar bulguları, tedavileri ile kanama ve tromboz durumlarını etkileyen faktörleri araştırmayı amaçladık. 2016- 2022 arası ET tanısı alan 270 hasta retrospektif incelendi, yaş ortalaması median 59 (19-92), %64’ü kadındı. Yüksek risk skoruna sahip olan JAK2 mutasyon pozitifliği %59 olup hastaların %39’ unda tromboz geliştiği (p=0.001), %23’ ünde kanama olduğu (p=0.008) saptandı. Ayrıca JAK2 pozitif olan hastaların çoğunun 60 yaş üstü olduğu (p=0.05), daha yüksek oranda miyelofibrozis geliştiği (p=0.007) görüldü. JAK2 mutasyonu pozitif hastaların, tanıda daha yüksek trombosit ve hemoglobin (Hb) değerine sahip olduğu bulundu (p=0.05, p=0.013). Hastalarımızın %33’ünde tanıda tromboz vardı (%89 arteryel ve %11 venöz trombozdu). Trombozu etkileyen risk durumları incelendiğinde; lökositoz, yüksek nötrofil ve Hb değeri ile istatistiksel anlamlılık saptandı (p=0.037, p=0.030, p=0.039). Multivariete analiz yapıldığında ise tromboz ile jak-2 pozitifliği ve lökositozun olması anlamlılığını koruyordu (p=0.022, p=0.006). Hastalarımızdan 217’si sağdı (%80). 10 yıllık sağkalım %75 olup, 60 yaş üstü hastalarda (p=0.001) ve tromboz olan hasta grubunda toplam sağkalım (OS) daha kısaydı (p=0.026). ELN risk skoru yüksek bulunan hastalarda sağkalım istatistiksel olarak anlamlı şekilde düşük saptandı (p=0.001) Revise-İPSET’ e göre orta ve yüksek skora sahip olanlarda sağkalım istatistiksel olarak anlamlı şekilde daha kısa bulundu (p=0.006). ET senelerce asemptomatik seyir gösterebileceği gibi, hayatı tehdit edebilen tromboembolik komplikasyonlar ve hemorajik durumlar ile karşımıza çıkmaktadır. Bu nedenle ET hastalarının yönetimi ve tedavi ihtiyacı olan yüksek riske sahip grubu tespit etmek önem taşımaktadır.